

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 223]3-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/828,995	04/09/2001	Catherine A. McCall	AL-7	9579
26949 7:	590 08/06/2003			
HESKA COR	PORATION		EXAMINER	
1613 PROSPE	AL PROPERTY DEPT. CT PARKWAY	SPECTOR, LORRAINE		
FORT COLLIN	NS, CO 80525		ART UNIT	PAPER NUMBER
			1647	20
			DATE MAILED: 08/06/2003	•

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Advisory Action**

	Application No.		Applicant(s)	
	09/828,995		MCCALL ET AL.	
Examiner		Art Unit		
Lorraine Spector, Ph.D.		1647		

-The MAILING DATE of this communication appears on the cover sheet with the correspondence address -

THE REPLY FILED 24 July 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.
PERIOD FOR REPLY [check either a) or b)]
a) $\square$ The period for reply expires $\underline{3}$ months from the mailing date of the final rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. The proposed amendment(s) will not be entered because:
(a) Ithey raise new issues that would require further consideration and/or search (see NOTE below);
(b) they raise the issue of new matter (see Note below);
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) they present additional claims without canceling a corresponding number of finally rejected claims.
NOTE: See Continuation Sheet.
3. Applicant's reply has overcome the following rejection(s):
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet</u> .
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
The status of the claim(s) is (or will be) as follows:
Claim(s) allowed: 63.
Claim(s) objected to: 61,62,65,71,76 and 77.
Claim(s) rejected: <u>60, 64, 66-70, 72-75, 78-80</u> .
Claim(s) withdrawn from consideration:
8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)
10. Other:
Jonain Spielo
Lorraine Spector, Ph.D. Primary Examiner

U.S. Patent and Trademark Office PTO-303 (Rev. 04-01) Art Unit: 1647

**Continuation Sheet (PTO-303)** 

-2.. **€** 



Application No. 009/828,995

Continuation of 2. NOTE: addition of limitation that peptide having percentage identity to reference sequence "elicits an immune response" to disclosed protien raises new issues under 35 USC 112, first paragraph for both written description and enablement. Additionally, claim 76 as amended has an "S" omitted from "SEQ ID NO:".

Amendments to claims 61, 66, 72 and 75, as well as cancellation of claims would be entered if submitted in a separate amendment.

Continuation of 5. does NOT place the application in condition for allowance because: rejections are maintained for reasons of record. Examiner suggested that claims to fragments of disclosed proteins that could be used to raise antibodies to the proteins would be allowable, NOT that fragments of proteins 95% identical to disclosed proteins that could be so used would be allowable...